Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
In an accompanying editorial, Janani Rangaswami, MD (Washington DC Veterans Affairs Medical Center), and colleagues say the findings represent a key opportunity to intensify CV-kidney therapies in real-world practice in high-risk CKD even without overt CVD being present, given comparable event rates and benefits from therapies. The numbers needed to treat to prevent one primary kidney outcome at 3 years amounted to 22 in those with ASCVD, 13 in those with HF, and 17 in those with a PREVENT score 20%
Most patients experiencing GLP-1 hair loss are dealing with temporary shedding related to telogen effluvium
Gabrielle Lyon to discuss muscle's vital role in longevity and how the novel nutrient Urolithin A supports muscle health
Ozempic is a GLP 1 antagonist
